CERE - Neurocrine Biosciences Looking At A Year Of Heavy Lifting
- Neurocrine exited 2021 with high single-digit qoq growth in Ingrezza prescriptions, but management is investing even more SG&A resources into recharging sales growth and momentum.
- Neurocrine has a large pipeline in terms of compounds and addressable indications, but the vast majority are early-stage high-risk programs.
- Phase II results from a study in essential tremor could add some value and excitement around midyear.
- Neurocrine shares still look undervalued, but will likely be lacking in catalysts for much of 2022.
For further details see:
Neurocrine Biosciences Looking At A Year Of Heavy Lifting